InterOcean Capital LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 52.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,034 shares of the medical research company’s stock after selling 1,123 shares during the quarter. InterOcean Capital LLC’s holdings in Thermo Fisher Scientific were worth $293,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in TMO. Blue Chip Wealth Management Inc. grew its stake in shares of Thermo Fisher Scientific by 1.3% during the 4th quarter. Blue Chip Wealth Management Inc. now owns 2,328 shares of the medical research company’s stock worth $756,000 after purchasing an additional 31 shares during the period. Kovitz Investment Group Partners LLC increased its holdings in Thermo Fisher Scientific by 4.0% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 802 shares of the medical research company’s stock valued at $261,000 after buying an additional 31 shares in the last quarter. Capital Bank & Trust Co increased its holdings in Thermo Fisher Scientific by 2.1% in the fourth quarter. Capital Bank & Trust Co now owns 1,509 shares of the medical research company’s stock valued at $490,000 after buying an additional 31 shares in the last quarter. Tiedemann Advisors LLC raised its position in shares of Thermo Fisher Scientific by 1.4% in the first quarter. Tiedemann Advisors LLC now owns 2,169 shares of the medical research company’s stock worth $616,000 after acquiring an additional 31 shares during the period. Finally, Main Street Research LLC boosted its stake in shares of Thermo Fisher Scientific by 2.8% during the 4th quarter. Main Street Research LLC now owns 1,187 shares of the medical research company’s stock worth $386,000 after acquiring an additional 32 shares in the last quarter. 88.68% of the stock is owned by institutional investors.
Shares of NYSE:TMO traded up $4.51 during midday trading on Friday, hitting $340.26. The company’s stock had a trading volume of 1,097,619 shares, compared to its average volume of 1,572,086. The company has a market cap of $132.60 billion, a P/E ratio of 37.31, a price-to-earnings-growth ratio of 2.25 and a beta of 1.04. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $351.86. The business’s 50 day simple moving average is $324.75 and its 200 day simple moving average is $317.43. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.69 and a current ratio of 2.32.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $2.94 EPS for the quarter, beating the Zacks’ consensus estimate of $2.79 by $0.15. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6.18 billion. Thermo Fisher Scientific had a net margin of 14.31% and a return on equity of 17.25%. Thermo Fisher Scientific’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.81 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 11.92 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, June 12th. This represents a $0.88 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.13%.
TMO has been the subject of a number of analyst reports. Citigroup upped their price target on Thermo Fisher Scientific from $365.00 to $390.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Needham & Company LLC upped their target price on Thermo Fisher Scientific from $341.00 to $383.00 in a research note on Thursday, April 23rd. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. BTIG Research boosted their price target on shares of Thermo Fisher Scientific from $342.00 to $372.00 and gave the stock an “in-line” rating in a report on Friday, January 31st. Finally, SVB Leerink increased their price objective on shares of Thermo Fisher Scientific from $330.00 to $365.00 and gave the company an “outperform” rating in a report on Thursday, April 23rd. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average price target of $347.21.
In other news, COO Mark Stevenson sold 25,000 shares of the business’s stock in a transaction dated Friday, April 24th. The shares were sold at an average price of $328.03, for a total transaction of $8,200,750.00. Following the transaction, the chief operating officer now owns 73,538 shares of the company’s stock, valued at approximately $24,122,670.14. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 30,000 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total transaction of $9,990,600.00. Following the completion of the sale, the chief executive officer now directly owns 304,946 shares of the company’s stock, valued at approximately $101,553,116.92. The disclosure for this sale can be found here. Company insiders own 0.45% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: Options Trading
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.